Recent studies have centered on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and DA neurotransmission. While GCGR stimulators are commonly employed for treating type 2 T2DM, their potential effects on reward circuits, specifically influenced by dopaminergic pathways, are receiving consid… Read More